New trial shows aspirin has no effect on dementia risk

But there’s just a hint of benefit that could be explored in bigger studies, the researchers say

Daily low-dose aspirin has again failed to impress as protective against dementia in a study of more than 15,000 patients with type 2 diabetes.

In the ASCEND study, the patients (mean age 63) were randomised to aspirin 100mg daily or placebo and followed for 7.4 years plus an additional 1.8 years after the trial.